The majority of cases were male (16, 64%) and left sided (17, 68%). Median age was 9 days (range 1 day to 11.6 years) at first ultrasound and 4.4
months (3 weeks to 12 years) at first renal scintigraphy. In 24 patients ultrasound correctly diagnosed a solitary kidney as confirmed by nuclear scan. In 1 patient ultrasound suggested a pelvic kidney but repeat ultrasound was negative, as was dimercapto-succinic acid scan. The diagnostic accuracy of ultrasound was 96%. Medicare reimbursement for dimercapto-succinic acid scan (CPT 78700) is $460 to $720 ($222 plus $240 for radiotracer plus $260 for anesthesia, if used).
Conclusions: Our findings suggest that ultrasonography alone is sufficient to make the diagnosis of solitary kidney. Omitting routine renal scintigraphy saves approximately $460 to $720 per case, and avoids radiation and discomfort without sacrificing diagnostic accuracy.”
“Therapeutic conditions for acute leukemia (AL) mainly rely on diagnosis BTSA1 nmr and detection of minimal residual disease (MRD). However, no serum biomarker has been
available for clinicians to make diagnosis of AL and assessment of MRD. In this study, we performed bead fractionation/MALDI-TOF-MS analysis on sera from patients with AL. Support vector machine algorithm was used to obtain diagnostic model that discriminated proteomic spectra of patients with AL from that of controls. Twenty-six features with p < 0.00001 had optimal discriminatory performance, with 97% sensitivity Tariquidar supplier and 100% specificity. Statistical analysis revealed that two peptides with m/z 1778 and 1865 were gradually decreased in their relative intensities with increase of remission degree. Moreover, the peptide with m/z 1865 was also found to be correlated with AL types. With FT-ICR-MS detection, both the peptides were identified as fragments of complement C3f. Linear regression analysis showed that the combined use of them could discriminate PML/RAR alpha positive M3 from molecular remission M3.
Two fragments of complement C3f were significantly correlated with MRD levels and could ADAM7 be used for clinical practice in MRD assessment.”
“Objective: The goal of this study was to develop dually radiolabeled peptides for simultaneous imaging of cancer cell localization by targeting the alpha(v)beta(3) integrin and their pathophysiology by targeting the activity of the proteolytic enzyme MMP2, involved in the metastatic process.
Methods: A hybrid peptide c(RGDfE)K(DOTA)PLGVRY containing an RGD motif for binding to the alpha(v)beta(3)integrin, a metal chelator (DOTA) for radiolabeling with [Cu-64], and the MMP2 substrate cleavage sequence PLGVRY with terminal tyrosine for labeling with [I-123] was synthesized, labeled with [Cu-64] and [I-123], and evaluated in vitro as a potential imaging agent.
Results: The peptide was synthesized and labeled with [Cu-64] and [I-123] with 300 and 40 mu Ci/mu g (542 and 72.